Developing science,
delivering therapies

4d

Our company

We are pioneers in harnessing bacteria as a revolutionary new class of medicines – called live biotherapeutics.

Our approach
developing-science

Developing science

From asthma to cancer, we conduct world-leading research to identify live biotherapeutics with drug-like functionality to treat a range of diseases.

What we do
delivering-therapies

Delivering therapies

We are uniquely positioned to rapidly translate our research into regulated, safe and efficacious therapies for patients.

Find out more

News

4D hosts R&D webinar discussing the world-leading MicroRx® LBP discovery platform
4D pharma's Research Director, Dr Imke Mulder, and members of her Research team provide an overview of the MicroRx® platfrom. The presentation is followed by an insightful Q&A session with invited analysts
Clinical Update - comprehensive clinical benefit data from Part A of combination trial of MRx0518 and Keytruda®
4D pharma announces complete 6-month clinical benefit data from Part A of its ongoing trial of Live Biotherapeutic MRx0518 in combination with Keytruda
Clinical Update - 4D pharma treats first cancer patients in Part B of Phase I/II trial of MRx0518 in combination with Keytruda®
4D commences treatment of the first patients in Part B of its Phase I/II clinical trial of MRx0518 in combination with immune checkpoint inhibitor Keytruda® (pembrolizumab) in patients with acquired resistance to prior immune checkpoint therapy.

Press release archive

RNS archive

BACK TO TOP